Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit, Cerebrovascular Remodeling, and Neurovascular Trophic Coupling in Alzheimer's Disease Model Mouse

Journal of Alzheimer's Disease

Volumn 52, Issue 1, 2016, Pages 113-126

  Shang, Jingwei ^a   Yamashita, Toru ^a   Zhai, Yun ^a   Nakano, Yumiko ^a   Morihara, Ryuta ^a   Fukui, Yusuke ^a   Hishikawa, Nozomi ^a   Ohta, Yasuyuki ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; APP23 mice; cerebrovascular remodeling; chronic cerebral hypoperfusion; galantamine; neurovascular trophic coupling 2016 IOS Press and the authors. All rights reserved.; neurovascular unit

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BUNGAROTOXIN RECEPTOR; GALANTAMINE; GELATINASE B; IMMUNOGLOBULIN G; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR REMODELING; CHRONIC CEREBRAL HYPOPERFUSION; COMMON CAROTID ARTERY; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE DEGENERATION; NEUROVASCULAR COUPLING; NEUROVASCULAR TROPHIC COUPLING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THALAMUS; VASCULAR REMODELING; ANIMAL; BRAIN; C57BL MOUSE; CEREBROVASCULAR DISORDERS; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GALANTAMINE; HUMANS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; NEUROVASCULAR COUPLING; NOOTROPIC AGENTS; RECEPTORS, NICOTINIC;

EID: 84973160894     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151126     Document Type: Article

References (48)

1. Hishikawa N, Fukui Y, Sato K, Kono S, Yamashita T, Ohta Y, Deguchi K, Abe K (2015) Characteristic features of cognitive, affective and daily living functions of late-elderly dementia. Geriatr Gerontol Int, doi: 10.1111/ggi.12492 [Epub ahead of print]
2. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10, 122-126
3. Wevers A, Witter B, Moser N, Burghaus L, Banerjee C, Steinlein OK, Schutz U, de Vos RA, Steur EN, Lindstrom J, SchroderH(2000) Classical Alzheimer features and cholinergic dysfunction: Towards a unifying hypothesis? Acta Neurol Scand 176 (Suppl), 42-48
4. Girouard H, Iadecola C (2006) Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol (1985) 100, 328-335
5. Jellinger KA, Mitter-Ferstl E (2003) The impact of cerebrovascular lesions in Alzheimer disease-A comparative autopsy study. J Neurol 250, 1050-1055
6. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113
7. Lourenco CF, Ledo A, Dias C, Barbosa RM, Laranjinha J (2015) Neurovascular and neurometabolic derailment in aging and Alzheimer's disease. Front Aging Neurosci 7, 103
8. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738
9. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM (2005) Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam Study. Ann Neurol 57, 789-794
10. Koriyama Y, Furukawa A, Muramatsu M, Takino J, Takeuchi M (2015) Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SHSY5Y human neuroblastoma cells. Sci Rep 5, 13313
11. Sasaki N, Fukatsu R, Tsuzuki K, HayashiY,Yoshida T, Fujii N, Koike T,Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153, 1149-1155
12. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, MaelickeA(2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305, 1024-1036
13. Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, Shimohama S (2004) Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 325, 976-982
14. Yanagida T, Takeuchi H, Kitamura Y, Takata K, Minamino H, ShibaikeT, Tsushima J, Kishimoto K,Yasui H,Taniguchi T, Shimohama S (2008) Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci Res 62, 254-261
15. Abe K (2013) [Nicotinic acetylcholine receptor in Alzheimer's disease]. Nihon Rinsho 71, 743-750
16. Tokuchi R, Hishikawa N, Matsuzono K, Takao Y, Wakutani Y, Sato K, Kono S, Ohta Y, Deguchi K, Yamashita T, Abe K (2015) Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease. Geriatr Gerontol Int, doi: 10.1111/ggi.12488 [Epub ahead of print]
17. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW Jr, Davis L, Vargas HM (1996) Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277, 728-738
18. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA,Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer diseaselike pathology. Proc Natl Acad Sci U S A 94, 13287-13292
19. Sturchler-Pierrat C, StaufenbielM(2000) Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci 920, 134-139
20. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, Deyn PP (2004) Altered circadian locomotor activity in APP23 mice: A model for BPSD disturbances. Eur J Neurosci 20, 2757-2766
21. Van Dam D, Abramowski D, Staufenbiel M, Deyn PP (2005) Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180, 177-190
22. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, JuckerM(2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21, 1619-1627
23. Augustin HG, Braun K, Telemenakis I, Modlich U,KuhnW (1995) Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 147, 339-351
24. Kitamura A, Fujita Y, Oishi N, Kalaria RN, Washida K, Maki T, Okamoto Y, Hase Y, Yamada M, Takahashi J, Ito H, Tomimoto H, Fukuyama H, Takahashi R, IharaM(2012) Selective white matter abnormalities in a novel rat model of vascular dementia. Neurobiol Aging 33, 1012.e25-35
25. He XL,Wang YH, Bi MG, DuGH(2012) Chrysin improves cognitive deficits and brain damage induced by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 680, 41-48
26. Kitagawa K, Yagita Y, Sasaki T, Sugiura S, Omura-Matsuoka E, Mabuchi T, Matsushita K, Hori M (2005) Chronic mild reduction of cerebral perfusion pressure induces ischemic tolerance in focal cerebral ischemia. Stroke 36, 2270-2274
27. Farkas E, Luiten PG, Bari F (2007) Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 54, 162-180
28. Adibhatla RM, Hatcher JF (2008) Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 41, 560-567
29. Urabe T (2012) [Molecular mechanism and new protective strategy for ischemic white matter damages]. Rinsho Shinkeigaku 52, 908-910
30. Bang J, Jeon WK, Lee IS, Han JS, Kim BY (2013) Biphasic functional regulation in hippocampus of rat with chronic cerebral hypoperfusion induced by permanent occlusion of bilateral common carotid artery. PLoS One 8, e70093
31. Zhao Y, Gu JH, Dai CL, Liu Q, Iqbal K, Liu F, Gong CX (2014) Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice. Front Aging Neurosci 6, 10
32. McKay BE, Placzek AN, Dani JA (2007) Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 74, 1120-1133
33. Liu Q, Xie XT, Lukas RJ, St John PA, Wu J (2013) A novel nicotinic mechanism underlies beta-amyloid-induced neuronal hyperexcitation. J Neurosci 33, 7253-7263
34. Takata K, KitamuraY, Saeki M, Terada M, Kagitani S, Kitamura R, Fujikawa Y, Maelicke A, Tomimoto H, Taniguchi T, Shimohama S (2010) Galantamine-induced amyloid-beta clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285, 40180-40191
35. Ni RQ, Marutle A, Nordberg A (2013) Modulation of alpha 7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's disease brain. J Alzheimers Dis 33, 841-851
36. Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) Howdoes diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6, 551-559
37. Yarchoan M, Arnold SE (2014) Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63, 2253-2261
38. Perrone L, Grant WB (2015) Observational and ecological studies of dietary advanced glycation end products in national diets and Alzheimer's disease incidence and prevalence. J Alzheimers Dis 45, 965-979
39. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201
40. Sweeney MD, Sagare AP, Zlokovic BV (2015) Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J Cereb Blood Flow Metab 35, 1055-1068
41. Arbel-Ornath M, Hudry E, Eikermann-Haerter K, Hou S, Gregory JL, Zhao LZ, Betensky RA, Frosch MP, Greenberg SM, Bacskai BJ (2013) Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer's disease mouse models. Acta Neuropathol 126, 353-364
42. ElAli A, Theriault P, Prefontaine P, Rivest S (2013) Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation. Acta Neuropathol Commun 1, 75
43. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N (2009) Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flowdisturbances. Neurobiol Aging 30, 1936-1948
44. Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ (2003) Cerebral amyloid angiopathy in the elderly: Vessel walls changes and relationship with dementia. Acta Neuropathol 106, 367-373
45. Faraco G, Iadecola C (2013) Hypertension: A harbinger of stroke and dementia. Hypertension 62, 810-817
46. Martinez-Lemus LA, Hill MA, Meininger GA (2009) The plastic nature of the vascularwall:Acontinuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda) 24, 45-57
47. Deane R, DuYan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C,Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913
48. Navaratna D, Fan X, Leung W, Lok J, Guo S, Xing C, Wang X, Lo EH (2013) Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain. J Clin Invest 123, 3373-3377